News about "Strides Pharma Science"

Strides Pharma Reports 21.3 Percent Growth in US Revenue in 9MFY25

Strides Pharma Reports 21.3 Percent Growth in US Revenue in 9MFY25

The gross margin stood at INR 6,735 million, marking a 25.1 percent rise compared to the same quarter last year.

Strides Pharma Science | 31/01/2025 | By Aishwarya

Strides Gets Approval from Equity Shareholders for Launch of OneSource

Strides Gets Approval from Equity Shareholders for Launch of OneSource

This is a critical step in the creation of OneSource and the support from Shareholders and Secured Creditors underscores the confidence in the company’s strategic initiative to create OneSource - India’s first specialty pharma Contract Development and Manufacturing Organization (CDMO).

Strides Pharma Science | 11/09/2024 | By Aishwarya 270

Strides Pharma Receives FDA Approval for Antidepressant Drug

Strides Pharma Receives FDA Approval for Antidepressant Drug

Strides Pharma Science’s subsidiary has gained approval from the US health regulator to market a generic antidepressant medication.

Strides Pharma Science | 10/04/2024 | By Aishwarya 367

Strides Gets USFDA Approval for Mycophenolate Mofetil for Oral Suspension

Strides Gets USFDA Approval for Mycophenolate Mofetil for Oral Suspension

The company has 280 cumulative ANDA filings with USFDA.

Strides Pharma Science | 31/08/2023 | By Manvi 478

Strides flagship facility in Bengaluru receives US FDA inspection closure

Strides flagship facility in Bengaluru receives US FDA inspection closure

The company's flagship facility was inspected by the US FDA between December 5 and 9, 2022, and a form 483 listing three inspectional observations was issued

Strides Pharma Science | 24/02/2023 | By Sudeep Soparkar 395

Strides Pharma completes WHO PQ inspection at Puducherry facility

Strides Pharma completes WHO PQ inspection at Puducherry facility

The inspection was carried out between January 16-20, 2023

Strides Pharma Science | 23/01/2023 | By Sudeep Soparkar 553

Strides Pharma's Bengaluru facility receives EIR from US FDA

Strides Pharma's Bengaluru facility receives EIR from US FDA

The abbreviated Quality System Inspection Technique (QSIT) drug pre-approval on-site inspection was specifically conducted by the US FDA

Strides Pharma Science | 18/01/2023 | By Sudeep Soparkar 284


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members